Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.68)
# 180
Out of 5,147 analysts
143
Total ratings
53.97%
Success rate
43.6%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $68.98 | +117.45% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $62.22 | +73.58% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $4.16 | +116.35% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $26.86 | +56.37% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $23.29 | +71.75% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $5.91 | +103.05% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $10.14 | +57.79% | 20 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $54.18 | +36.58% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $432.00 | +29.63% | 13 | Sep 29, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $30.09 | +82.78% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $18.25 | +53.42% | 1 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.74 | +434.76% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $4.31 | +317.63% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.45 | +244.83% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.99 | +50.75% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.78 | +155.31% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $11.92 | +67.79% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.92 | +56.25% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $21.18 | +65.25% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $63.27 | -39.94% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $33.84 | +183.69% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.09 | +37.61% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $8.21 | +1,605.24% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.44 | +2,516.28% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.33 | +4,704.80% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $2.61 | +91.57% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.28 | +1,829.82% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.42 | +2,531.58% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.29 | +442.64% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.01 | +445,444.55% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.38 | +195,552.17% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $8.23 | +835.60% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.61 | +235,386.51% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.98 | +34.23% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $91.59 | -57.42% | 2 | Mar 18, 2020 |
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $68.98
Upside: +117.45%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $62.22
Upside: +73.58%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $4.16
Upside: +116.35%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $26.86
Upside: +56.37%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $23.29
Upside: +71.75%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $5.91
Upside: +103.05%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $10.14
Upside: +57.79%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $54.18
Upside: +36.58%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $432.00
Upside: +29.63%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $30.09
Upside: +82.78%
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $18.25
Upside: +53.42%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $3.74
Upside: +434.76%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.31
Upside: +317.63%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.45
Upside: +244.83%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.99
Upside: +50.75%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.78
Upside: +155.31%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $11.92
Upside: +67.79%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.92
Upside: +56.25%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $21.18
Upside: +65.25%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $63.27
Upside: -39.94%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $33.84
Upside: +183.69%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.09
Upside: +37.61%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $8.21
Upside: +1,605.24%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.44
Upside: +2,516.28%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.33
Upside: +4,704.80%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $2.61
Upside: +91.57%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.28
Upside: +1,829.82%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.42
Upside: +2,531.58%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.29
Upside: +442.64%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.01
Upside: +445,444.55%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.38
Upside: +195,552.17%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $8.23
Upside: +835.60%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.61
Upside: +235,386.51%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.98
Upside: +34.23%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $91.59
Upside: -57.42%